查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949488

基因組癌症檢測及分析市場－全球產業規模、佔有率、趨勢、機會及預測：組織檢測、癌症檢測類型、癌症類型、應用、技術、終端用戶、地區及競爭格局，2021-2031年

Genomic Cancer Panel & Profiling Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Tissue Testing, By Cancer Panel Type, By Cancer Type, By Application, By Technology, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因組癌症檢測和分析市場預計將從 2025 年的 110.9 億美元成長到 2031 年的 191.6 億美元，複合年成長率為 9.54%。

這些診斷技術專注於對特定基因或基因組區域定序，以識別驅動腫瘤發生的突變和變化。市場成長趨勢的主要促進因素是全球癌症發生率的上升（這需要個人化的治療策略）以及次世代定序工作流程成本的下降。這些因素共同推動了分子診斷在臨床實踐中的廣泛應用，以最佳化標靶治療方案。

市場概覽
預測期 2027-2031
市場規模：2025年 110.9億美元
市場規模：2031年 191.6億美元
複合年成長率：2026-2031年 9.54%
成長最快的細分市場 液體組織檢測
最大的市場 北美洲

日益加重的疾病負擔進一步推動了這項需求。美國癌症協會預測，到2024年，美國新增癌症病例將首次超過200萬例。儘管需求如此明確，但市場仍面臨與複雜的報銷結構相關的重大障礙。全面的分子譜分析保險覆蓋範圍不一致仍然是一個主要障礙，這可能會阻礙其廣泛應用，並限制患者獲得這些重要的檢測服務。

市場促進因素

非侵入性液態生物檢體活體組織切片技術的快速發展是推動市場成長的主要動力，它克服了傳統組織取樣的限制。這些基於血液的檢測方法能夠檢測循環腫瘤DNA，從而實現對疾病進展和抗藥性機制的即時追蹤，且無需承擔手術切片檢查的風險。臨床檢測量的成長也印證了微創診斷技術的普及。例如，Guardant Health在2024年11月發布的第三季財報中宣布，其臨床檢測量年增21%，達到53,100例，顯示這些技術在臨床應用中正迅速普及。

同時，生物標記主導的藥物研發興起，推動了對綜合基因組檢測的需求，以識別標靶治療候選藥物。製藥公司正大力投資精準腫瘤產品組合，推動了伴隨診斷的需求。例如，輝瑞在2024年第三季財報（2024年10月）中指出，收購Seegen的產品組合為其腫瘤部門貢獻了8.54億美元的收入，這體現了生物標記標標靶治療的商業性價值。這項投資也與疾病負擔的長期預測相符。世界衛生組織（WHO）下屬的國際癌症研究機構（IARC）在2024年預測，到2050年，全球癌症患者人數將超過3500萬，凸顯了可擴展診斷解決方案的迫切性。

市場挑戰

複雜的報銷環境和參差不齊的保險覆蓋範圍對全球基因組癌症檢測和分析市場的擴張構成了重大障礙。當支付結構不明確或難以預測時，臨床實驗室和醫院系統往往不願意將全面的基因組分析納入常規診療流程。這種財務上的不確定性迫使醫療機構依賴範圍更窄、成本更低的診斷測試以避免拒付，阻礙了廣泛的次世代定序檢測的普及。因此，醫療機構的財務管理人員通常認為這些先進診斷技術的經濟風險超過了其臨床效益，限制了市場擴張。

此外，支付方政策的不一致限制了診斷公司的整體檢測量和商機。由於缺乏標準化的強制規定，患者往往面臨高昂的自付費用和較高的檢測中止率。根據美國癌症協會癌症行動網路（American Cancer Society Cancer Action Network）統計，截至2024年，僅有16個州頒布了法律，保障全面的生物標記檢測，這意味著美國大部分人口仍面臨分散且限制性強的保險選擇。這種監管碎片化導致市場結構依賴地域條件和保險計劃類型，而非臨床需求，從而有效地抑制了市場滲透和成長。

市場趨勢

將人工智慧 (AI) 應用於數據解讀正在改變市場格局，有效應對海量基因組資料集的分析挑戰。隨著定序結果日益複雜，AI 演算法對於獲取臨床洞見和檢測人工分析可能遺漏的罕見突變模式至關重要。這種技術融合正在推動商業性應用，診斷公司正利用 AI 來提升精準醫療能力並提高營運效率。例如，Tempus AI 在 2025 年 1 月發布的「2024 會計年度第四季及全年初步業績」中報告稱，全年營收約為 6.93 億美元，同比成長 30%。這一成長主要得益於該公司 AI 驅動的精準醫療和基因組分析解決方案的廣泛應用。

同時，市場正經歷著向全面基因組分析（CGP）的明顯轉變，從窄範圍的熱點基因panel轉向廣譜定序。這項轉變的驅動力來自新興的臨床數據，這些數據表明，與窄範圍的診斷方法相比，大規模的panel能夠識別出更多可靶向的突變，並提高患者獲得適當治療方法。這一顯著的臨床優勢正促使醫療系統將更廣泛的檢測通訊協定標準化，以確保不錯過任何治療機會。正如Illumina在2024年11月關於此次合作的新聞稿中所指出的，真實世界數據顯示，接受CGP檢測的患者中，67%的腫瘤攜帶可靶向的突變，而接受50基因panel檢測的患者中，這一比例僅為33%。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球基因組癌症檢測及分析市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過組織檢測（固態組織檢測、液體組織檢測）
    • 依癌症檢測組合類型（單基因檢測、多基因檢測）
    • 癌症類型（肺癌、乳癌、結腸癌、攝護腺癌、其他）
    • 按應用領域（臨床、研究）
    • 依技術分類（次世代定序（NGS）、聚合酵素鏈鎖反應（PCR）、螢光原位雜合反應（FISH）、免疫組織化學（IHC）、其他）
    • 依最終使用者（醫院、臨床/診斷檢查室、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美基因組癌症檢測及分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲基因組癌症檢測及分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區基因組癌症檢測及分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東及非洲基因組癌症檢測及分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲基因組癌症檢測及分析市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球基因組癌症檢測及分析市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies, Inc.
  • ARUP Laboratories Inc
  • Burning Rock Biotech Limited
  • US Caris MPI, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23883

The Global Genomic Cancer Panel & Profiling Market is projected to expand from a valuation of USD 11.09 Billion in 2025 to USD 19.16 Billion by 2031, registering a CAGR of 9.54%. These diagnostic technologies focus on sequencing specific genes or genomic regions to pinpoint mutations and alterations that fuel tumor development. The market's upward trajectory is largely driven by the growing global incidence of cancer, which demands personalized therapeutic strategies, alongside the decreasing costs associated with next-generation sequencing workflows. Together, these factors encourage the incorporation of extensive molecular diagnostics into clinical settings to optimize targeted treatment planning.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 11.09 Billion
Market Size 2031USD 19.16 Billion
CAGR 2026-20319.54%
Fastest Growing SegmentLiquid tissue testing
Largest MarketNorth America

This demand is intensified by the increasing disease burden; the American Cancer Society projects that new cancer cases in the United States will exceed 2 million for the first time in 2024. Despite this evident need, the market contends with significant hurdles related to complex reimbursement structures. Inconsistent insurance coverage for comprehensive molecular profiling continues to be a major obstacle, potentially limiting widespread adoption and restricting patient access to these critical testing capabilities.

Market Driver

The rapid growth of non-invasive liquid biopsy profiling serves as a major market accelerator by addressing the constraints of conventional tissue sampling. These blood-based assays facilitate the detection of circulating tumor DNA, allowing for real-time tracking of disease progression and resistance mechanisms without the dangers linked to surgical biopsies. The shift toward less invasive diagnostics is underscored by increasing clinical testing volumes; for instance, Guardant Health reported in its November 2024 Third Quarter Financial Results that clinical test volume rose 21% year-over-year to 53,100 tests, signaling rapid clinical adoption of these tools.

Concurrently, the rise in biomarker-driven drug development requires the use of comprehensive genomic panels to identify candidates for targeted therapies. Pharmaceutical companies are heavily investing in precision oncology portfolios, fueling the need for companion diagnostics. Highlighting the commercial value of biomarker-targeted treatments, Pfizer reported in its October 2024 Third Quarter Results that oncology revenue was bolstered by an $854 million contribution from the acquired Seagen portfolio. This investment aligns with long-term forecasts of disease burden, as the World Health Organization's International Agency for Research on Cancer predicted in 2024 that global cancer cases will exceed 35 million by 2050, emphasizing the urgency for scalable diagnostic solutions.

Market Challenge

Complicated reimbursement landscapes and inconsistent insurance coverage represent substantial obstacles to the expansion of the Global Genomic Cancer Panel & Profiling Market. Clinical laboratories and hospital systems are often reluctant to incorporate comprehensive genomic profiling into routine care when payment structures are unclear or unpredictable. This financial instability forces healthcare providers to depend on narrower, less costly diagnostic tests to prevent claim denials, which hinders the uptake of broader next-generation sequencing panels. Consequently, market expansion is stifled because financial administrators at medical facilities often view the economic risks of these advanced diagnostics as outweighing their clinical benefits.

Furthermore, the lack of uniformity in payer policies limits the total volume of testing and restricts revenue opportunities for diagnostic firms. Without standardized mandates, patients frequently encounter prohibitive out-of-pocket expenses, resulting in high rates of test abandonment. According to the American Cancer Society Cancer Action Network in 2024, only 16 states had enacted legislation guaranteeing coverage for comprehensive biomarker testing, leaving most of the United States population facing fragmented and restrictive insurance decisions. This regulatory patchwork creates a market where access depends more on geography and insurance plan type than on clinical necessity, effectively capping market penetration and growth.

Market Trends

The integration of Artificial Intelligence in Data Interpretation is transforming the market by addressing the challenge of analyzing vast genomic datasets. As sequencing outputs increase in complexity, AI algorithms have become crucial for deriving clinical insights and detecting rare variant patterns that might be overlooked during manual analysis. This technological convergence is driving commercial adoption, with diagnostic companies utilizing AI to refine precision medicine capabilities and boost operational efficiency. For example, Tempus AI reported in its January 2025 Preliminary Fourth Quarter and Full Year 2024 Results that full-year revenue reached approximately $693 million, marking a 30% year-over-year increase attributed largely to the strong adoption of its AI-powered precision medicine and genomic profiling solutions.

At the same time, the market is undergoing a distinct transition toward Comprehensive Genomic Profiling (CGP), moving away from limited hotspot panels in favor of broad-spectrum sequencing. This evolution is driven by emerging clinical data indicating that larger panels identify a significantly higher number of actionable alterations, thereby enhancing patient access to matched therapies relative to narrower diagnostic methods. This distinct clinical advantage is prompting healthcare systems to standardize broader testing protocols to reduce missed treatment opportunities. As noted by Illumina in a November 2024 press release regarding a new joint study, real-world evidence showed that 67% of tumors from CGP-tested patients contained actionable mutations, compared to just 33% in patients assessed with smaller 50-gene panels.

Key Market Players

  • Agilent Technologies, Inc.
  • ARUP Laboratories Inc
  • Burning Rock Biotech Limited
  • U.S. Caris MPI, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Cancer Panel & Profiling Market, By Tissue Testing

  • Solid Tissue Testing
  • Liquid Tissue Testing

Genomic Cancer Panel & Profiling Market, By Cancer Panel Type

  • Single-Gene Panel
  • Multi-Gene Panel

Genomic Cancer Panel & Profiling Market, By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colon Cancer
  • Prostate Cancer
  • Others

Genomic Cancer Panel & Profiling Market, By Application

  • Clinical
  • Research

Genomic Cancer Panel & Profiling Market, By Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescence In-Situ Hybridization (FISH)
  • Immunohistochemistry (IHC)
  • Others

Genomic Cancer Panel & Profiling Market, By End-User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Others

Genomic Cancer Panel & Profiling Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomic Cancer Panel & Profiling Market.

Available Customizations:

Global Genomic Cancer Panel & Profiling Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Cancer Panel & Profiling Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
    • 5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
    • 5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
    • 5.2.4. By Application (Clinical, Research)
    • 5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
    • 5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2025)
  • 5.3. Market Map

6. North America Genomic Cancer Panel & Profiling Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Tissue Testing
    • 6.2.2. By Cancer Panel Type
    • 6.2.3. By Cancer Type
    • 6.2.4. By Application
    • 6.2.5. By Technology
    • 6.2.6. By End-User
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Tissue Testing
        • 6.3.1.2.2. By Cancer Panel Type
        • 6.3.1.2.3. By Cancer Type
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By Technology
        • 6.3.1.2.6. By End-User
    • 6.3.2. Canada Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Tissue Testing
        • 6.3.2.2.2. By Cancer Panel Type
        • 6.3.2.2.3. By Cancer Type
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By Technology
        • 6.3.2.2.6. By End-User
    • 6.3.3. Mexico Genomic Cancer Panel & Profiling Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Tissue Testing
        • 6.3.3.2.2. By Cancer Panel Type
        • 6.3.3.2.3. By Cancer Type
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By Technology
        • 6.3.3.2.6. By End-User

7. Europe Genomic Cancer Panel & Profiling Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Tissue Testing
    • 7.2.2. By Cancer Panel Type
    • 7.2.3. By Cancer Type
    • 7.2.4. By Application
    • 7.2.5. By Technology
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Tissue Testing
        • 7.3.1.2.2. By Cancer Panel Type
        • 7.3.1.2.3. By Cancer Type
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By Technology
        • 7.3.1.2.6. By End-User
    • 7.3.2. France Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Tissue Testing
        • 7.3.2.2.2. By Cancer Panel Type
        • 7.3.2.2.3. By Cancer Type
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By Technology
        • 7.3.2.2.6. By End-User
    • 7.3.3. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Tissue Testing
        • 7.3.3.2.2. By Cancer Panel Type
        • 7.3.3.2.3. By Cancer Type
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By Technology
        • 7.3.3.2.6. By End-User
    • 7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Tissue Testing
        • 7.3.4.2.2. By Cancer Panel Type
        • 7.3.4.2.3. By Cancer Type
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By Technology
        • 7.3.4.2.6. By End-User
    • 7.3.5. Spain Genomic Cancer Panel & Profiling Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Tissue Testing
        • 7.3.5.2.2. By Cancer Panel Type
        • 7.3.5.2.3. By Cancer Type
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By Technology
        • 7.3.5.2.6. By End-User

8. Asia Pacific Genomic Cancer Panel & Profiling Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Tissue Testing
    • 8.2.2. By Cancer Panel Type
    • 8.2.3. By Cancer Type
    • 8.2.4. By Application
    • 8.2.5. By Technology
    • 8.2.6. By End-User
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Tissue Testing
        • 8.3.1.2.2. By Cancer Panel Type
        • 8.3.1.2.3. By Cancer Type
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By Technology
        • 8.3.1.2.6. By End-User
    • 8.3.2. India Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Tissue Testing
        • 8.3.2.2.2. By Cancer Panel Type
        • 8.3.2.2.3. By Cancer Type
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By Technology
        • 8.3.2.2.6. By End-User
    • 8.3.3. Japan Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Tissue Testing
        • 8.3.3.2.2. By Cancer Panel Type
        • 8.3.3.2.3. By Cancer Type
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By Technology
        • 8.3.3.2.6. By End-User
    • 8.3.4. South Korea Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Tissue Testing
        • 8.3.4.2.2. By Cancer Panel Type
        • 8.3.4.2.3. By Cancer Type
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By Technology
        • 8.3.4.2.6. By End-User
    • 8.3.5. Australia Genomic Cancer Panel & Profiling Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Tissue Testing
        • 8.3.5.2.2. By Cancer Panel Type
        • 8.3.5.2.3. By Cancer Type
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By Technology
        • 8.3.5.2.6. By End-User

9. Middle East & Africa Genomic Cancer Panel & Profiling Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Tissue Testing
    • 9.2.2. By Cancer Panel Type
    • 9.2.3. By Cancer Type
    • 9.2.4. By Application
    • 9.2.5. By Technology
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Tissue Testing
        • 9.3.1.2.2. By Cancer Panel Type
        • 9.3.1.2.3. By Cancer Type
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By Technology
        • 9.3.1.2.6. By End-User
    • 9.3.2. UAE Genomic Cancer Panel & Profiling Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Tissue Testing
        • 9.3.2.2.2. By Cancer Panel Type
        • 9.3.2.2.3. By Cancer Type
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By Technology
        • 9.3.2.2.6. By End-User
    • 9.3.3. South Africa Genomic Cancer Panel & Profiling Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Tissue Testing
        • 9.3.3.2.2. By Cancer Panel Type
        • 9.3.3.2.3. By Cancer Type
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By Technology
        • 9.3.3.2.6. By End-User

10. South America Genomic Cancer Panel & Profiling Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Tissue Testing
    • 10.2.2. By Cancer Panel Type
    • 10.2.3. By Cancer Type
    • 10.2.4. By Application
    • 10.2.5. By Technology
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Tissue Testing
        • 10.3.1.2.2. By Cancer Panel Type
        • 10.3.1.2.3. By Cancer Type
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By Technology
        • 10.3.1.2.6. By End-User
    • 10.3.2. Colombia Genomic Cancer Panel & Profiling Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Tissue Testing
        • 10.3.2.2.2. By Cancer Panel Type
        • 10.3.2.2.3. By Cancer Type
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By Technology
        • 10.3.2.2.6. By End-User
    • 10.3.3. Argentina Genomic Cancer Panel & Profiling Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Tissue Testing
        • 10.3.3.2.2. By Cancer Panel Type
        • 10.3.3.2.3. By Cancer Type
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By Technology
        • 10.3.3.2.6. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Genomic Cancer Panel & Profiling Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. ARUP Laboratories Inc
  • 15.3. Burning Rock Biotech Limited
  • 15.4. U.S. Caris MPI, Inc.
  • 15.5. Danaher Corporation
  • 15.6. Exact Sciences Corporation
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Fulgent Genetics Inc.
  • 15.9. Illumina, Inc.
  • 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer